Research programme: integrin receptor antagonists - Johnson & Johnson Pharmaceutical Research and Development, LLC

Drug Profile

Research programme: integrin receptor antagonists - Johnson & Johnson Pharmaceutical Research and Development, LLC

Alternative Names: 3DP-229300; 3DP-336036

Latest Information Update: 06 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class Hydroxyquinolines; Propionic acids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders

Most Recent Events

  • 10 Sep 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections ,
  • 02 Aug 2004 A preclinical study has been added to the Cancer pharmacodynamics section
  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top